Hagens Berman Targets Erasca Over Oncology Drug Misrepresentations

The lawsuit alleges that between January 14, 2025, and April 26, 2026, Erasca executives misrepresented the competitive standing and safety profile of their pan-RAS molecular glue. According to the complaint, the company allegedly utilized flawed preclinical data to claim superiority over rival therapies, such as Revolution Medicines' RMC-6236, while simultaneously downplaying significant patent infringement vulnerabilities and clinical trial hazards.

The truth behind these claims surfaced in late April 2026, when Erasca revealed a legal challenge from Revolution Medicines and disclosed a patient death in its ERAS-0015 trial. This information triggered a market correction that erased over $2.8 billion in the company's capitalization. Reed Kathrein, a partner at Hagens Berman, stated that the firm is investigating whether these omissions were part of an intentional effort to mislead shareholders regarding the company's intellectual property moat and clinical safety.

Investors who acquired shares during the specified period are encouraged to contact Hagens Berman to discuss potential recovery options. Beyond the class action, the firm is also soliciting information from whistleblowers who may possess non-public details regarding the company’s internal practices, noting that such disclosures could be eligible for rewards under SEC programs.